AHNAK2 and central nervous system cancer: Conversely, lower expression levels of AHNAK2 were observed in glioblastoma multiforme, glioma (GBMLGG), brain lower grade glioma, breast invasive carcinoma, and prostate adenocarcinoma (Fig. 5A).